Radiation and immunotherapy combo shows promise against esophageal cancer
NCT ID NCT07682376
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial explores whether adding low-dose radiotherapy and an immunotherapy drug (retlirafusp alfa) to standard chemotherapy before surgery can improve outcomes for people with a type of esophageal cancer that has spread locally but can still be removed. The study enrolls about 96 adults aged 18-75 with resectable esophageal squamous cell carcinoma. Participants receive either the full combination or the immunotherapy plus chemotherapy alone, followed by surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
low-dose radiotherapy, retlirafusp alfa, nab-paclitaxel, cisplatin/carboplatin
What this could lead to
If successful, this combination could become a new standard pre-surgery treatment, potentially increasing the chance of complete tumor removal and long-term survival.
What could go wrong
This is an early phase 2 study with a small number of participants. The added treatments may increase side effects, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Short-Course Radiotherapy + Tislelizumab for Eso NCT07678580
- Adebrelimab Combo for Esophageal Cancer Trial NCT07638436
- HS-20093 for Esophageal Cancer Trial (NCT07621601)
- Biomarkers for PD-1 inhibitor response in SCC | NCT07147361
- Adalimumab Combo for Esophageal Cancer (NCT07595770)
- Pembrolizumab for Esophageal Cancer Trial (NCT04210115)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, China
Harbin, Heilongjiang, 150081, China